Short Interest in Universe Pharmaceuticals INC (NASDAQ:UPC) Declines By 83.4%

Posted by Dante Gardener on May 14th, 2026

Universe Pharmaceuticals INC (NASDAQ:UPC – Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 764 shares, a drop of 83.4% from the April 15th total of 4,610 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 7,018 shares, the days-to-cover ratio is currently 0.1 days.

Universe Pharmaceuticals Stock Performance

Universe Pharmaceuticals stock traded up $0.04 on Thursday, hitting $2.71. 2,570 shares of the stock traded hands, compared to its average volume of 13,477. The business’s fifty day simple moving average is $2.83 and its 200 day simple moving average is $3.53. Universe Pharmaceuticals has a 1 year low of $2.00 and a 1 year high of $11.00.

Universe Pharmaceuticals (NASDAQ:UPC – Get Free Report) last posted its quarterly earnings results on Thursday, January 29th. The company reported $0.69 earnings per share (EPS) for the quarter. The company had revenue of $8.92 billion during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Check Out Our Latest Report on Universe Pharmaceuticals

About Universe Pharmaceuticals

(Get Free Report)

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.